A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Titre officiel

A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Sommaire:

Il s’agit d’une étude ouverte à groupe unique sur l’utilisation de l’idasanutline en monothérapie chez les participants atteints de polycythémie vraie (PV) qui n’ont pas répondu à l’hydroxyurée (HU) ou qui ne la tolèrent pas.

Description de l'essai

Primary Outcome:

  • Percentage of Ruxolitinib-Naïve Participants With Splenomegaly at Baseline who Achieved Composite Response at Week 32
  • Percentage of Ruxolitinib-Naïve Participants Without Splenomegaly at Baseline who Achieved Hematocrit (Hct) Control Without Phlebotomy at Week 32
  • Percentage of All Ruxolitinib-Naïve Participants (Irrespective of Spleen Size) who Achieved Hct Control Without Phlebotomy at Week 32
  • Percentage of All Ruxolitinib-Resistant or Intolerant Participants who Achieved Hct Control Without Phlebotomy at Week 32
Secondary Outcome:
  • Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants who Achieved Complete Hematologic Response at Week 32
  • Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants who Achieved Complete Hematologic Remission at Cycle 11 Day 28
  • Duration of Complete Hematologic Remission, with a Durable Responder Defined as a Participant in Remission at Week 32 and Cycle 11 Day 28
  • Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline by Response per Modified European Leukemia Net (ELN) Criteria
  • Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline by Response per Modified ELN Criteria
  • Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) by Response per Modified ELN Criteria
  • Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks from Week 32
  • Duration of Response, in Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline with Durable Response Lasting at Least 12 Weeks From Week 32
  • Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks from Week 32
  • Duration of Response, in Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline with Durable Response Lasting at Least 12 Weeks From Week 32
  • Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) With Durable Response Lasting at Least 12 Weeks from Week 32
  • Duration of Response, in All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) with Durable Response Lasting at Least 12 Weeks From Week 32
  • Total Number of Participants With Adverse Events by Severity, Graded According to NCI CTCAE v4.0
  • Percentage of Participants With Clinical Laboratory Abnormalities: Hematology Parameters
  • Percentage of Participants With Clinical Laboratory Abnormalities: Clinical Chemistry Parameters
  • Percentage of Participants With Clinical Laboratory Abnormalities: Urinalysis Parameters
  • Change from Baseline in Electrocardiogram Parameters: PQ(PR), QRS, QT, QTcB, QTcF, and RR Durations
  • Change from Baseline in Heart Rate, as Measured by Electrocardiogram
  • Change from Baseline in Oral Temperature
  • Change from Baseline in Pulse Rate
  • Change from Baseline in Respiratory Rate
  • Change from Baseline in Systolic Blood Pressure
  • Change from Baseline in Diastolic Blood Pressure
  • Eastern Cooperative Oncology Group (ECOG) Performance Status Over Time
  • Percentage of Participants With Concomitant Medications
  • Maximum Serum Concentration Observed (Cmax) of Idasanutlin
  • Trough Concentration (Ctrough) of Idasanutlin
  • Time of Maximum Concentration Observed (tmax) of Idasanutlin
  • Clearance (CL) of Idasanutlin
  • Apparent Clearance (CL/F) of Idasanutlin
  • Volume or Apparent Volume of Distribution (Vdss/F) of Idasanutlin
  • Area Under the Concentration-Time Curve (AUC) of Idasanutlin
  • Half-life (t1/2) of Idasanutlin
  • Baseline and Mean Change from Baseline Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Over Time
  • Baseline and Mean Change from Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scores Over Time
  • Frequency Count of Participant Responses to the Patient Global Impression of Change (PGIC) Question Over Time

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer